| abstract |
A pharmaceutical composition comprising a proteasome inhibitor having the structure ** Formula ** and a cyclodextrin for use in the treatment of inflammation, neurodegenerative disease, muscle wasting disease, cancer, chronic infectious disease, fever, a condition related to immunity, denervation or nerve injury, to inhibit or reduce HIV infection, to affect the level of viral gene expression in a subject, or to alter the diversity of antigenic peptides produced by the proteasome in an organism, in which cyclodextrin is a beta-cyclodextrin substituted with one or more hydrophilic groups. |